Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum
November 02 2023 - 11:48AM
Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane
Biotech”) in partnership with ProgenaCare Global LLP
(“ProgenaCare”) today announces the launch of the newly rebranded
revyve™ Antimicrobial Wound Gel (formerly coactiv+™ Antimicrobial
Wound Gel).
“We are excited to share this cutting-edge product and the new
revyve™ brand with the larger wound care community. Clinicians who
have been exposed to the product so far have really appreciated the
combination of advanced technology with an affordable price point.
We are working to expand clinical usage of the product in advance
of full production scale-up in Q1,” stated Howard Walthall, CEO of
ProgenaCare.
The product rebranding is being unveiled as part of Kane’s
participation in the Symposium on Advanced Wound Care (SAWC) Fall
forum. The conference will take place on November 2-5, 2023 in Las
Vegas, Nevada and is intended to connect the entire wound care team
fostering inclusivity, innovation and interdisciplinary
collaboration. During this conference, Kane Biotech and ProgenaCare
will present along with other important voices in the Biotech and
Wound Care sectors.
Kane’s revyve™ Antimicrobial Wound Gel is a combination of its
patented coactiv+™ technology and PHMB, paired with a non-ionic
pluronic surfactant with thermo-gelling properties. The combination
of these three components provides for a moist environment best
suited for wound healing, with effective antimicrobial activity in
an easy-to-use gel that is optimized for sensitive wounds.
“The first step of the healing process in the treatment of
chronic non-healing wounds is to clear out the infection. Kane’s
team, in collaboration with ProgenaCare, chose the name “revyve” to
symbolize the revival of the healing process. I am excited about
the results of this collaboration with ProgenaCare which is a great
start to our long-term partnership,” stated Marc Edwards, President
and CEO of Kane Biotech.
More information about Kane’s revyve™ Antimicrobial Wound Gel
can be found at www.revyvegel.com.
About revyve™ Antimicrobial Wound Gel
revyve™ Antimicrobial Wound Gel is indicated
for management of ulcers (including diabetic foot and leg ulcers
and pressure ulcers), 1st and 2nd degree burns, partial & full
thickness wounds, large surface area wounds and surgical incisions
for adult populations. It is also indicated for management of minor
skin scrapes, minor cuts, minor lacerations, minor burns (1st
degree burns) and abrasions for adult populations.
revyve™ Antimicrobial Wound Gel is a clear,
odorless hydrogel that provides a moist wound environment conducive
to wound healing. coactiv+™ Antimicrobial Wound
Gel can facilitate debridement through a moist wound
environment.
About ProgenaCare (ProgenaCare Global LLC)
ProgenaCare is a purpose-driven medical device company
leveraging cutting-edge advances in biomaterials and medical device
technologies to provide effective, affordable advanced wound care
solutions to patients across the socioeconomic spectrum and around
the world.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research,
development and commercialization of technologies and products that
prevent and remove microbial biofilms. The Company has a portfolio
of biotechnologies, intellectual property (80 patents and patents
pending, trade secrets and trademarks) and products developed by
the Company's own biofilm research expertise and acquired from
leading research institutions. StrixNB™, DispersinB®, Aledex™,
bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®,
DermaKB™, DermaKB Biofilm™, and revyve™ are trademarks of Kane
Biotech Inc. The Company is listed on the TSX Venture Exchange
under the symbol "KNE" and on the OTCQB Venture Market under the
symbol “KNBIF”.
|
|
|
Marc
Edwards |
Ray Dupuis |
Nicole
Sendey |
Chief Executive Officer |
Chief Financial Officer |
Investor Relations/PR |
Kane Biotech Inc |
Kane Biotech Inc |
Kane Biotech Inc |
medwards@kanebiotech.com |
rdupuis@kanebiotech.com |
nsendey@kanebiotech.com |
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Caution Regarding Forward-Looking
InformationThis press release contains certain statements regarding
Kane Biotech Inc. that constitute forward-looking information under
applicable securities law. These statements reflect
management’s current beliefs and are based on information currently
available to management. Certain material factors or assumptions
are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in
such statements. These risks and uncertainties include, but are not
limited to, risks relating to the Company’s: (a) financial
condition, including lack of significant revenues to date and
reliance on equity and other financing; (b) business, including its
early stage of development, government regulation, market
acceptance for its products, rapid technological change and
dependence on key personnel; (c) intellectual property including
the ability of the Company to protect its intellectual property and
dependence on its strategic partners; and (d) capital structure,
including its lack of dividends on its common shares, volatility of
the market price of its common shares and public company costs.
Further information about these and other risks and uncertainties
can be found in the disclosure documents filed by the Company with
applicable securities regulatory authorities, available
at www.sedar.com. The Company cautions that the foregoing list
of factors that may affect future results is
not exhaustive.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/d257e7cf-da77-4800-862d-bcdb7892b0d1
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Kane Biotech (TSXV:KNE)
Historical Stock Chart
From Jan 2024 to Jan 2025